Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease.

I H Young, E Daviskas, V A Keena

Department of Thoracic Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Low dose nebulised morphine may relieve dyspnoea through a direct effect on lung afferent nerves. To study this further 11 adult patients with advanced chronic lung disease (FEV1 range 0.4-1.41), whose exercise endurance was limited by dyspnoea, were entered into a double blind, randomised, crossover study in which low dose morphine or a placebo was inhaled. The effects were assessed by an endurance exercise test at 80% of maximum work load. One hour after a control endurance test patients inhaled 5 ml of morphine 1 mg/ml or isotonic saline for 12 minutes from a jet nebuliser. An endurance exercise test was repeated 15 minutes later and change in endurance time recorded. The two endurance tests were repeated on a separate day, before and after inhalation of the alternative solution. In all tests 100% oxygen was inhaled from a demand valve. The mean (SD) increase in endurance time was significantly greater after the subjects had inhaled morphine (64.6 (115) s, 35%) than after placebo (8.9 (55) s, 0.8%; p less than 0.01). The mean dose of morphine nebulised was 1.7 (0.66) mg, giving a mean inhaled dose of about 0.6 mg, on the assumption of 30% retention of the nebulised dose by each patient. No side effects were reported. Possibly small amounts of morphine delivered to the lungs act directly on lung afferent nerves to reduce dyspnoea.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., Zielinski, J. (2007). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 176: 532-555 [Abstract] [Full Text]  
• Shirk, M. B., Donahue, K. R., Shirvani, J. (2006). Unlabeled uses of nebulized medications.. Am J Health Syst Pharm 63: 1704-1716 [Abstract] [Full Text]  
• Brown, S. J, Eichner, S. F, Jones, J. R (2005). Nebulized Morphine for Relief of Dyspnea Due to Chronic Lung Disease. The Annals of Pharmacotherapy 39: 1088-1092 [Abstract] [Full Text]  
• Burki, N. K., Dale, W. J., Lee, L.-Y. (2005). Intravenous adenosine and dyspnea in humans. J. Appl. Physiol. 98: 180-185 [Abstract] [Full Text]  
• Foral, P. A., Malesker, M. A., Huerta, G., Hilleman, D. E. (2004). Nebulized Opioids Use in COPD. Chest 125: 691-694 [Abstract] [Full Text]  
• LeGrand, S. B., Khawam, E. A., Walsh, D., Rivera, N. I. (2003). Opioids, respiratory function, and dyspnea. AM J HOSP PALLIAT CARE 20: 57-61 [Abstract]  
• Jennings, A-L, Davies, A N, Higgins, J P T, Gibbs, J S R, Broadley, K E (2002). A systematic review of the use of opioids in the management of dyspnoea. Thorax 57: 939-944 [Abstract] [Full Text]  
• PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., HURD, S. S. (2001). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease . NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am. J. Respir. Crit. Care Med. 163: 1256-1276 [Full Text]  
• Webb, M., Moody, L. E., Mason, L. A. (2000). Dyspnea assessment and management in hospice patients with pulmonary disorders. AM J HOSP PALLIAT CARE 17: 259-264 [Abstract]  
• Davis, C. L. (1999). Letter to the editor. AM J HOSP PALLIAT CARE 16: 543-543  
• Atkinson, C. V, Kirkham, S. R (1999). Unlicensed uses for medication in a palliative care unit. Palliat Med 13: 145-152 [Abstract]  
• Zeppetella, G. (1998). The palliation of dyspnea in terminal disease. AM J HOSP PALLIAT CARE 15: 322-330 [Abstract]  
• POOLE, P. J., VEALE, A. G., BLACK, P. N. (1998). The Effect of Sustained-Release Morphine on Breathlessness and Quality of Life in Severe Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 157: 1877-1880 [Abstract] [Full Text]  
• Robinson, W. M., Ravilly, S., Berde, C., Wohl, M. E. (1997). End-of-Life Care in Cystic Fibrosis. Pediatrics 100: 205-209 [Abstract] [Full Text]  
• Zeppetella, G. (1997). Nebulized morphine in the palliation of dyspnoea. Palliat Med 11: 267-275 [Abstract]  
• Stein, W. M., Min, Y. K. (1997). Nebulized morphine for paroxysmal cough and dyspnea in a nursing home resident with metastatic cancer. AM J HOSP PALLIAT CARE 14: 52-56  
• Shee, C. D (1995). Palliation in chronic respiratory disease. Palliat Med 9: 3-12 [Abstract]  
• Davis, C L, Hardy, J R (1994). Current Issues in Cancer Palliative care. BMJ 308: 1359-62 [Full Text]  
• Ripamonti, C., Bruera, E. (1992). Review articles : Transdermal and inhalatory routes of opioid administration: the potential application in cancer pain. Palliat Med 6: 98-104 [Abstract]  
• McDonald, P., Graham, P., Clayton, M., Buhagiar, A., Stuart-Harris, R. (1991). Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med 5: 323-329 [Abstract]  
• de Conno, F., Spoldi, E., Caraceni, A., Ventafridda, V. (1991). Does pharmacological treatment affect the sensation of breathlessness in terminal cancer patients?. Palliat Med 5: 237-243 [Abstract]  
• Regnard, C., Ahmedzai, S. (1991). Dyspnoea in advanced nonmalignant disease - a flow diagram. Palliat Med 5: 56-60 [Abstract]  
• Regnard, C., Ahmedzai, S. (1990). Dyspnoea in advanced cancer - a flow diagram. Palliat Med 4: 311-315 [Abstract]